People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Biotechnology, Pharmaceuticals, Other Technology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ViaCyte Inc. | — | Biotechnology | Series C | $149.6M | $1.7B | 2013 |
| Chimerix Inc | — | Pharmaceuticals | Series C | $96.0M | $1.2B | 2019 |
| Stereotaxis, Inc. | — | Other Technology | Series B | $70.5M | $21.8M | 2012 |
| Endocyte Inc | — | Biotechnology | Series B | $53.7M | $321.5M | 2009 |
| LineaGen Inc | — | Other Health Care | Series B | $49.7M | $269.7M | 2010 |
| Cylene Pharmaceuticals, Inc. | — | Biotechnology | Series B | $22.6M | $34.4M | 2010 |
| Axikin Pharmaceuticals Inc | — | Pharmaceuticals | Series A | $15.5M | $201.3M | 2010 |
| Theravida, Inc. | — | Other Health Care | Series A | $9.1M | $1.6M | 2023 |
| Novocell, Inc | — | Biotechnology | Pre-Seed | $304K | $16.8M | 2010 |
Fred A. Middleton at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Fred A. Middleton on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.